One of the major complications by metabolic syndrome is chronic kidney disease (CKD). 37 million American adults have CKD and millions of others are at increased risk.

Current medicines cannot reverse CKD. RB394 can potentially become the first treatment available as it demonstrates efficacy against CKD by reducing renal inflammation, oxidative stress, tubular injury, and vascular injury.
Two main causes of chronic kidney disease are diabetes and high blood pressure, which are often associated with metabolic syndrome.


The global Chronic Kidney Disease drugs market was valued at US$ 12.4 billion in 2016, and is expected to reach US$ 17.4 billion by 2025, expanding at a CAGR of 4% from 2017 to 2025.

About Us

MetaSyn Therapeutics develops breakthrough technology for treating metabolic syndrome and its related diseases.

We seek medical and/or technological partners to bring the drug to the market.